BullFrog AI stock soars 101% after striking pharma deal for depression drug discovery

Shares of BullFrog AI surged by more than 101% in a single trading session after the company announced a partnership with a top-five global pharmaceutical firm. The deal focuses on using BullFrog's AI technology to discover and rank drug targets for major depressive disorder (MDD). Meanwhile, the company's warrant ticker, BFRGW, also climbed over 35% during the same period. The partnership centres on BullFrog AI's bfLEAP platform, which uses causal network inference to analyse complex biological data. Under the agreement, the pharmaceutical partner secures exclusive rights to one target candidate identified through the technology. CEO Vin Singh highlighted the deal as a major endorsement of the company's AI-driven approach.

BullFrog AI's technology suite includes three key components: bfLEAP for target discovery, bfPREP for data preparation, and bfARENAS for portfolio optimisation. The company has positioned itself as a leader in AI-assisted drug development, particularly in mental health. With the MDD treatment market valued at over $8 billion in 2025 and expected to reach $11 billion by 2032, the sector's growth potential remains strong. While no specific milestones or timelines for depression drug development have been disclosed, BullFrog AI remains optimistic about future commercial partnerships. The company's track record in target discovery and portfolio optimisation has bolstered confidence in its platform.

The sharp rise in BullFrog AI's stock reflects investor confidence in its AI-driven drug discovery capabilities. The partnership with a leading pharmaceutical company underscores the growing demand for advanced tools in mental health treatment. With the MDD market expanding steadily, the company's technology could play a key role in shaping future therapies.